Beta-Blockers for Congestive Heart Failure

Comprehensive Therapy

Volumn 29, Issue 4, 2003, Pages 210-214

  Sorrentino, Matthew J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; METOPROLOL;

ADRENERGIC SYSTEM; BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL PROTOCOL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE OVERLOAD; HUMAN; MORBIDITY; MORTALITY; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SURVIVAL;

ADRENERGIC BETA-ANTAGONISTS; HEART FAILURE, CONGESTIVE; HUMANS; PATIENT SELECTION; TREATMENT OUTCOME;

EID: 0345743557     PISSN: 00988243     EISSN: None     Source Type: Journal    
DOI: 10.1385/COMP:29:4:210     Document Type: Review

References (16)

1. The CONSENSUS Trial Study Group. The effects of enalapril on mortality in severe congestive heart failure. N Engl J Med. 1987;316:1429-1435.
2. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
3. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.
4. Carson PE. Beta blocker treatment in heart failure. Prog Cardiovasc Dis. 1999;41:301-322.
5. Bristow MR. β-Adrenergic receptor blockade in chronic heart failure. Circulation. 2000;101:558-569.
6. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomized controlled trial. Lancet. 2003;362:7-13.
7. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 1975;37:1022-1036.
8. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet. 1979;1:1264-1266.
9. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993;342:1441-1446.
10. Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: A double-blind, randomized, placebo-controlled trial. Circulation. 1985;72:536-546.
11. Garg RK, Sorrentino MJ. Beta blockers for CHF: Adrenergic blockade dramatically reduces morbidity and mortality. Postgrad Med. 2001;109:49-56.
12. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355.
13. Packer M, Coats AJ, Fowler MB, et al. Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658.
14. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study-II (CIBIS-II): A randomized trial. Lancet. 1999;353:9-13.
15. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007.
16. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659-67.